Cystic Fibrosis Patents (Class 514/851)
-
Patent number: 5725842Abstract: Methods are disclosed for removing retained mucus secretions from the lungs of a human subject. The method includes (1) generating an aerosol suspension of respirable solid, dry particulate amiloride, and (2) delivering by inhalation the aerosol suspension to the respiratory system of the subject. The solid particulate amiloride is comprised of particles of about 1 to 5 microns and is free of liquid amiloride particles. The aerosol suspension of respirable solid particulate amiloride is administered in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of from about 10.sup.-7 to 10.sup.-3 Moles/liter. As a result of the treatment, the secretions are hydrated and more easily transported from the lung via mucociliary action. Methods are also disclosed for the treatment of cystic fibrosis in humans.Type: GrantFiled: January 5, 1996Date of Patent: March 10, 1998Assignee: The University of North Carolina at Chapel HillInventors: Richard C. Boucher, Jr., Michael R. Knowles
-
Patent number: 5708034Abstract: Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising themSulfonimidamides of the formula I ##STR1## in which at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, and in which the other substituents have the meanings indicated in the claims, are outstandingly suitable as medicaments having action on the cardiovascular system; that is as antiarrhythmic pharmaceuticals having a cardioprotective component as well as for treating ischemically induced damage; also in operative interventions, such as organ transplantation.Type: GrantFiled: October 31, 1996Date of Patent: January 13, 1998Assignee: Hoechst AktiengesellschaftInventors: Heinz-Werner Kleemann, Joachim Brendel, Jan-Robert Schwark, Andreas Weichert, Hans Jochen Lang, Udo Albus, Wolfgang Scholz
-
Patent number: 5698537Abstract: The use of phospholipids of the following formula to reduce the viscosity of mucus in a patient is described: ##STR1## wherein one of X, Y, or Z represent: ##STR2## in which each R represents hydrogen or methyl, and each of the other two of X, Y, or Z represents --CO--R.sup.1 in which R.sup.1 represents linear or branched C.sub.11-21 alkyl or C.sub.11-21 alkenyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, C.sub.1-6 linear or branched alkoxy or cyano.Type: GrantFiled: June 18, 1996Date of Patent: December 16, 1997Assignee: Clarion Pharmaceuticals Inc.Inventor: Thaddeus P. Pruss
-
Patent number: 5686114Abstract: Pharmaceutical compositions comprising an inorganic pyrophosphate (PPi) in a form that renders the PPi accessible to ABC proteins when administered to a subject in vivo, as well as use of the compositions for treating subjects having a disease or disorder associated with inappropriate or inadequate ABC protein activity (e.g., cystic fibrosis, multi drug resistance, Zellweger's Syndrome) is disclosed.Type: GrantFiled: June 2, 1995Date of Patent: November 11, 1997Assignee: University of Iowa Research FoundationInventor: Michael J. Welsh
-
Patent number: 5674898Abstract: Methods and compositions for treating Cystic Fibrosis by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.Type: GrantFiled: June 7, 1993Date of Patent: October 7, 1997Assignee: Genzyme CorporationInventors: Seng Hing Cheng, Shaona Lee Fang, Henry Hoppe, IV, Alan Edward Smith
-
Patent number: 5674483Abstract: The present invention relates to a method to protect an animal from a disease involving inflammation by treating that animal with an effective amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory disease involving an inflammatory response and a method for monitoring the success of a treatment for a respiratory disease involving an inflammatory response in an animal. Also included in the present invention is a formulation comprising IL-12 and a compound capable of enhancing the effectiveness of the IL-12 at protecting an animal from a disease involving inflammation.Type: GrantFiled: January 31, 1995Date of Patent: October 7, 1997Assignee: National Jewish Medical and Research CenterInventors: Yuan-Po Tu, Charles G. Irvin
-
Patent number: 5656256Abstract: Method of hydrating lung mucous secretions in the lungs of a subject are disclosed. The methods involve administering benzamil or phenamil to the lungs of the subject in an amount effective to hydrate lung mucous secretions. The administering step is preferably carried out by inhalation administration. The method is useful in the treatment of diseases such as cystic fibrosis and chronic bronchitis.Type: GrantFiled: December 14, 1994Date of Patent: August 12, 1997Assignee: The University of North Carolina at Chapel HillInventors: Richard C. Boucher, Monroe Jackson Stutts
-
Patent number: 5635160Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is disclosed: ##STR1## wherein: n is from 1 to 6;X is --OH or --SH;A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br. The compounds are useful in the treatment of airway diseases such as cystic fibrosis. Pharmaceutical formulations comprising a compound of Formula (I), and methods of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: June 3, 1997Assignee: The University of North Carolina at Chapel HillInventors: Monroe J. Stutts, III, Richard C. Boucher, Jr., Eduardo R. Lazarowski, Cara A. Geary
-
Patent number: 5602110Abstract: A method and composition for treating cystic fibrosis comprising administering to a patient a first component, a second component, and preferably a third component. The first component is an inhibitor which is specific for a cGMP-inhibited type III cAMP phosphodiesterase, preferably milrinone or amrinone; the second component is an adenylate cyclase activator, preferably forskolin, isoproterenol or albuterol; the third component is cAMP or a cAMP analog which activates protein kinase A.Type: GrantFiled: January 26, 1995Date of Patent: February 11, 1997Assignee: Case Western Reserve UniversityInventors: Mitchell L. Drumm, Thomas J. Kelley
-
Patent number: 5543399Abstract: A substantially homogeneous protein having cystic fibrosis transmembrane conductance regulator activity is provided. Also provided is a therapeutically effective composition for treating a subject having cystic fibrosis.Type: GrantFiled: October 13, 1994Date of Patent: August 6, 1996Assignee: HSC Research & Development Limited PartnershipInventors: John R. Riordan, Christine E. Bear, Mohabir Ramjeesingh, Canhui Li
-
Patent number: 5518729Abstract: In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient one or more N-substituted 2-(1H) pyridone(s). The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.Type: GrantFiled: May 16, 1994Date of Patent: May 21, 1996Inventor: Solomon B. Margolin
-
Patent number: 5514665Abstract: Methods for reducing the risk of or preventing infections by bacterial pathogens in vivo. In particular, a method for reducing the risk of P. aeruginosa infection in vivo in compromised hosts such as cystic fibrosis patients. The methods involve the use of dextran or dextran sulphate as the active ingredient.Type: GrantFiled: October 3, 1994Date of Patent: May 7, 1996Assignee: University of British ColumbiaInventors: David P. Speert, Thomas C. Usher
-
Patent number: 5512269Abstract: A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.Type: GrantFiled: June 9, 1993Date of Patent: April 30, 1996Assignees: Burroughs Wellcome, Co., University of North Carolina at Chapel HillInventors: Luis M. Molina y Vedia, Monroe J. Stutts, Richard C. Boucher, Jr., David C. Henke
-
Patent number: 5502039Abstract: O-derivatized alginic acid antigens capable of eliciting opsonizing antibodies in vivo are described. The O-derivatized antigens show enhanced antigenicity and immunogenicity relative to native, non-O-derivatized alginic acid antigens, particularly the MEP antigen of P. aeruginosa. Pharmaceutical compositions containing the O-derivatized antigens of the invention are also described. The invention also pertains to use of the compositions as vaccines, in immunodiagnostic assays, and in methods for producing monoclonal antibodies reactive against the antigen.Methods for forming O-derivatized alginic acid antigens of the invention are described. A non-O-derivatized starting material is reacted in a solvent with an alkyl anhydride derived from a fatty acid.Type: GrantFiled: July 11, 1994Date of Patent: March 26, 1996Assignee: Brigham and Women's Hospital, Inc.Inventor: Gerald Pier
-
Patent number: 5478569Abstract: Stable, cold water-dispersible, liquid or pulverous compositions of fat-soluble substances which contain fish gelatin as the protective colloid and a method of making same are described.Type: GrantFiled: November 28, 1994Date of Patent: December 26, 1995Assignee: Hoffmann-La Roche Inc.Inventors: Kurt Berneis, Peter Schuler
-
Patent number: 5474760Abstract: A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.Type: GrantFiled: March 29, 1994Date of Patent: December 12, 1995Assignee: Duke UniversityInventors: Andrew J. Ghio, Claude A. Piantadosi, Thomas P. Kennedy
-
Patent number: 5464817Abstract: The invention is generally directed to methods of promoting normal respiratory tract airflow in subjects with restricted airflow and ciliary clearance caused by the presence of pathological airway contents, and particularly mucoid contents. Actin-binding proteins are administered into the respiratory tract of a subject with a pathological respiratory condition involving the presence of such contents. The actin-binding protein binds to actin polymers in the contents and decreases the viscosity. The actin binding proteins also prevent actin from binding to exogenous or endogenous DNase, thus increasing the degradation of DNA polymers in the contents.Type: GrantFiled: April 2, 1993Date of Patent: November 7, 1995Assignee: Brigham and Women's HospitalInventors: Thomas P. Stossel, Stuart E. Lind, Paul A. Janmey
-
Patent number: 5441938Abstract: A novel therapy for Pseudomonas aeruginosa infections, in particular in cystic fibrosis patients, is described. Macrophages provide the first line of defence in protecting the lung against bacterial infections. Nonetheless, Pseudomonas aeruginosa infections continue to be problematic in cystic fibrosis patients and are the leading cause of death in these patients. Previously, little was known regarding the factors which regulate the capacity of macrophages to mediate phagocytosis of Pseudomonas aeruginosa. The inventors have now shown that phagocytosis of nonopsonized Pseudomonas aeruginosa by macrophages is dependent upon the presence of glucose. They have also shown that the action of glucose is on the macrophage rather than the bacteria. Glucose therapy can therefore be used to prevent or combat Pseudomonas aeruginosa infections.Type: GrantFiled: May 26, 1992Date of Patent: August 15, 1995Assignee: University of British ColumbiaInventors: David Speert, Sameer Barghouthi, Siamon Gordon
-
Patent number: 5384119Abstract: Oligomers of the formula ##STR1## have demonstrated effectiveness in preventing connective tissue damage.Type: GrantFiled: October 29, 1993Date of Patent: January 24, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventor: Michael J. Janusz
-
Patent number: 5310562Abstract: In a preferred embodiment, drugs having heretofore unknown pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone. The pharmaceutical composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.Type: GrantFiled: September 21, 1992Date of Patent: May 10, 1994Inventor: Solomon B. Margolin
-
Patent number: 5290815Abstract: The present invention provides a new medical use for the phenethanolamine compound 4-hydroxy-.alpha..sup.1 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol and physiologically acceptable salts and solvates thereof in the treatment of inflammation, allergy and allergic reaction.Type: GrantFiled: November 25, 1991Date of Patent: March 1, 1994Assignee: Glaxo Group LimitedInventors: Malcolm Johnson, Clifford J. Whelan
-
Patent number: 5250286Abstract: A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD where it is associated with asthma, comprises administering the imidazoline to a patient by inhalation. Preferably, the imidazoline compound employed is tolazoline. The presentation of an imidazoline compound in a device for the administration of an aerosol is disclosed.Type: GrantFiled: November 27, 1991Date of Patent: October 5, 1993Assignee: Aegis Technology, Inc.Inventor: Alvaro H. Skupin
-
Patent number: 5162361Abstract: The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a method for the treatment of such diseases in warm-blooded animals, such as humans, which comprises the administration of a therapeutically effective amount of an aromatic diamidine, sufficient to inhibit IL-1 release from IL-1 producing cells. The aromatic diamidine can also be used to block interleukin 6 (IL-6) and tumor necrosis factor from cells producing these cytokines.Type: GrantFiled: April 10, 1990Date of Patent: November 10, 1992Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Rosenthal, Yasuhida Kouchi, Emanuela Corsini, Benny Blaylock, Christine Comment, Michael Luster, William Craig, Michael Taylor
-
Patent number: 5128339Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.Type: GrantFiled: October 24, 1991Date of Patent: July 7, 1992Assignee: Sterling Winthrop Inc.Inventors: Richard P. Dunlap, Neil W. Boaz, Albert J. Mura, Virendra Kumar, Chakrapani Subramanyam, Ranjit C. Desai, Dennis J. Hlasta, Manohar T. Saindane, Malcolm R. Bell, John J. Court
-
Patent number: 5104862Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.Type: GrantFiled: March 20, 1991Date of Patent: April 14, 1992Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, Malcolm Maccoss
-
Patent number: 5100880Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.Type: GrantFiled: March 20, 1991Date of Patent: March 31, 1992Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, Malcolm Maccoss
-
Patent number: 5100647Abstract: Methods for the therapy of cystic fibrosis, Bartter's syndrome, and secretory diarrheas, and for diuretic treatment, by administering to a patient dodecahydro-7,14-methano-2H,6H-di-pyrido[1,2-a:1',2'-e][1,5]diazocine or a pharmaceutically acceptable derivative thereof are disclosed. The formulations include an aerosol formulation comprising the active ingredient in association with an aerosol propellant.Type: GrantFiled: October 2, 1990Date of Patent: March 31, 1992Assignee: The Trustees of the University of PennsylvaniaInventors: Zalman S. Agus, Ellie Kelepouris, Martin Morad
-
Patent number: 5096916Abstract: A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD where it is associated with asthma, comprises administering the imidazoline to a patient by inhalation. Preferably, the imidazoline compound employed is tolazoline. The presentation of an imidazoline compound in a device for the administration of an aerosol is disclosed.Type: GrantFiled: May 7, 1990Date of Patent: March 17, 1992Assignee: Aegis Technology, Inc.Inventor: Alvaro H. Skupin
-
Patent number: 4866072Abstract: A method of treatment of cystic fibrosis which comprises administration to a patient suffering from that condition of a therapeutically effective quantity of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or a pharmaceutically acceptable derivative thereof.Pharmaceutically acceptable salts of the active ingredient which may be used include alkali metal salts, in particular the di-sodium salt which is known as nedocromil sodium.Type: GrantFiled: February 18, 1988Date of Patent: September 12, 1989Assignee: Fisons plcInventors: Alan M. Edwards, Richard A. Foulds
-
Patent number: 4826679Abstract: The invention relates to an oral composition for alleviating digestive manifestations in patients afflicted with cystic fibrosis, which comprises a therapeutic amount of taurine in association with a pharmaceutically acceptable carrier, and to a method of alleviating digestive manifestations in patients afflicted with cystic fibrosis by the administration of said oral composition.Type: GrantFiled: May 23, 1986Date of Patent: May 2, 1989Assignee: Universite de MontrealInventor: Claude C. Roy
-
Patent number: 4737519Abstract: The present invention provides certain novel substituted naphthalenes, indoles, benzofurans, and benzothiophenes of Formula I which are useful as inhibitors of leukotriene biosynthesis and as inhibitors of lipoxygenase. They are thus employed wherever it is medically necessary or desirable to inhibit these systems.Type: GrantFiled: June 25, 1986Date of Patent: April 12, 1988Assignee: The Upjohn CompanyInventors: Ayako Yamashita, Herbert G. Johnson